Radioactive isotopes should and will play a major role in the advancement of 21st Century medicine. These medical isotopes are currently showing outstanding results in both diagnostic and therapeutic medical applications, which should continue to expand for application for essentially all the major diseases (cancer, heart, Alzheimer’s, arthritis, etc.) for the rest of this century. There have also been promising research results in killing the HIV virus with medical isotopes.

This paper briefly presents examples of these developments and their future promise for two forms of cancer (breast and liver), Alzheimer’s disease, and HIV. The promise of treatment with radioactive isotopes can be seen from one patient who was told, “You have three months to live” four years ago. Now, as a result of treatment with the medical isotope yttrium-90, applied using what are called Y90 microspheres, the patient not only is alive, but works out with a personal trainer every other day, and is living life to the fullest.

Introduction
Diagnostic and therapeutic medical isotope applications have made major advances for the past 50 years, and these advances should accelerate as we continue through the 21st Century. In the United States, and probably in the rest of the world, the aging of the World War II Baby Boomers will create an exponentially increasing demand for the medical application of these isotopes, as people live longer and acquire the diseases of aging.

Dr. Robert E. Schenter is one of the leading U.S. experts on fission reactor production of isotopes. Based on his 39 years as an expert on neutron cross-section and decay data information, he has become a world authority on isotope production. Now the chief science officer of the Advanced Medical Isotope Corporation, Schenter previously worked as the site director and deputy site director in the Isotope Program Office at the Westinghouse Hanford Company (WHC) and the Pacific Northwest National Laboratory (PNNL). In 1991, he was responsible for the relief of a world shortage of gadolinium-153, which is used in instruments for early detection of osteoporosis. He also defined the project and directed the production in the Fast Flux Test Facility (FFTF) in Richland, Washington.

This paper, which appeared in Executive Intelligence Review, Jan. 1, 2008, was prepared for the Schiller Institute conference on “Making the Eurasian Land-Bridge a Reality,” Sept. 15-16, 2007.
Half-Life

Breast Cancer

Anemia, Human Bone Marrow

Diagnostic Cancers: Cervical, Colon, Colorectal, Cancers: Chest, Chronic Lymphocytic, Glioblastoma, Liver, Multiple Myeloma, Prostate, Urinary Tract

Diseases: Alzheimer’s, Brain, Epilepsy, Heart, Parkinson’s

Alcohol Addiction, Amphetamine Release, Drug Addiction, Neuropsychiatric, Nicotine Dependence, Pain Processing, Schizophrenia, Small Animal Imaging, Tobacco Addiction

Cerebral and Myocardial Perfusion, Colorectal Cancer, Human Biodistribution, Liver Cancer, Renal Blood Flow, Renal Injury

Cancers: Cervical, Colon, Colorectal, Lymphoma, Melanoma, Pancreatic, Prostate

Diseases: Angiogeneses, Brain, Hypoxia, Parkinson’s, Wilson’s Stem Cell Research

Cancers: Adrenal Gland, Anal, Bone, Bone Marrow Transplants, Bowel, Breast, Cervical, Chest, Colorectal, Esophageal, Gastric, Head and Neck, Hodgkin’s Disease, Laryngeal, Leukemia, Liver, Lung (NSCLC), Lung(SCLC), Melanoma, Multiple Myeloma, non-Hodgkin’s Lymphoma, Osseous, Ovarian, Pancreatic, Prostate, Rectal, Rhabdomyosarcoma, Squamous Cell, Thyroid, Urinary, Vocal Cord

Diseases: Alcohol Addiction, Alzheimer’s, Anorexia, Atherosclerosis, Brain, Depression, Diabetes, Heart, Herpes, HIV, Hypoxia, Infection, Liver, Muscle, Kennedy’s Narcolepsy, Lung Inflammation, Osteomyelitis, Parkinson’s, Pneumonia, Ulcerative Colitis, Schizophrenia, Tourette’s Syndrome

Infection: Pen-Prosthetic, Hip-Prosthetic, Joint-Prosthetic

Small Animal Imaging, Chemotherapy Research

Breast Cancer, Heart Imaging, Immunoscintigraphy, Molecular Imaging, Neuroendocrine Tumors, Pancreatic Cancer

Apoposis, Cancer Biotherapy, Glioma, Heart Disease, Mediastinal Micrometastases, Scouting of Therapeutic Radioimmunoconjugates, Thyroid Cancer

Anemia, Human Bone Marrow

Ammonia Dog Studies, Coronary Artery Disease, Diabetes, Gamma Camera, Heart Disease, Imaging of Heart, Pancreas and Liver, Lupus Erythematosus, Myocardial Perfusion, Pulmonary Ventilation

Acute Brain Injury, Arterial Blood Flow, Brain Cancer, Oxygen Utilization, Brain Studies, Cerebral Blood Volume, Cerebral Responses, Coronary Artery Vasospasm, Coronary Reserve, Heart Disease, Ischemic Stroke Disease, Kinetics of Oxygen, Liver Cancer, Myocardial Viability, Oxygen Metabolism, Pain Control, Venous Ulceration

Heart Disease, Myocardial Perfusion, Sarcoidosis

Distribution of Y90, Lung Cancer, Melanoma, Renal Cell Carcinoma

Brain Tumors, Head and Neck Cancers, non-Hodgkin’s Lymphoma

Source: Dr. Robert E. Schenter, Ph.D.
An ultrasound-guided breast brachytherapy procedure, in which a radioactive “seed” is inserted into a tiny balloon, placed at the site of the surgically removed tumor. The seed delivers the prescribed dose of radiation directly to the site where cancer recurrence is most likely, minimizing exposure to healthy tissue in the breast, skin, ribs, lungs, and heart. This outpatient treatment can be for one to five days. No source of radiation remains in the patient’s body between treatments or after the procedure is completed.

Liver Cancer
A medical breakthrough called microsphere brachytherapy is giving new hope to patients with liver cancer. This therapy works by delivering radiation from the medical isotope yttrium-90 through a catheter tube, directly to tumors inside the liver. The yttrium-90 is contained in tiny glass bead microspheres. Several million of these Y-90 microspheres are used in a single treatment.

According to Dr. Andrew Kennedy of Raleigh, N.C., the Y-90 microspheres are delivered into the liver, where they reside permanently in the tumors; and the radiation is designed to penetrate only about one-quarter of an inch into the tissue. So, as the tumor is being destroyed, the nearby normal liver tissue is not being affected. The outpatient procedure takes about one hour.

Alzheimer’s Disease
Currently, more than 5 million Americans have Alzheimer’s disease. Symptoms vary considerably, but usually begin with a tendency to forget, which becomes so severe that it affects the patient’s social life, family life, work, and recreational hobbies. Alzheimer’s is the most common form of dementia, and is the result of brain aging.

The two major methods of diagnosing Alzheimer’s disease both use medical isotopes: Single Photon Emission Tomography (SPECT) and Positron Emission Tomography (PET).

With SPECT, a small amount of gamma-ray-emitting isotope (for example, technetium-99m or thallium-201) is bound to neuro-specific pharmaceuticals and then injected into a patient’s vein, from where it is taken into the brain tissue. The isotope fixes itself onto the brain with proportional flow, emitting a gamma ray which is picked up and detected by a SPECT gamma camera.

PET is a way of getting three-dimensional images or maps of functional processes of the body (see box). For Alzheimer’s disease, PET scan images use the isotopes carbon-11 or fluorine-18, to compare normal brain activity to reduced brain activity. A PET scan can show the brain’s biological changes attributable to Alzheimer’s disease earlier than any other diagnostic test can provide this information. Alzheimer’s disease can even be detected several years earlier than the onset of symptoms.

The application of PET for Alzheimer’s disease is rapidly spreading in use at medical clinics and hospitals all over the
NUCLEAR MEDICINE

Technologies We Can’t Afford to Ignore
by Marjorie Mazel Hecht

Nuclear medicine, the use of radioactive isotopes in diagnosing and treating disease, has a proven track record of saving lives, and saving money, by providing faster and better diagnostic results and cancer treatment with no unpleasant or dangerous side-effects. But although many nuclear medicine techniques were pioneered in the United States, today this country lags behind in research, development, training, and treatment.

In Europe, where nuclear medicine is overtaking standard chemotherapy treatment for certain types of cancer, a patient is more likely to find the most advanced treatment, using radioisotopes.

Every aspect of nuclear medicine is underfunded and underdeveloped here. Most striking is the fact that the United States must import more than 90 percent of the medical radioisotopes used. When you consider that 20 million diagnostic and treatment procedures are performed annually here with radioisotopes, this level of “outsourcing” is staggering.

Eighty percent of the medical radioisotopes used in the United States come from Canada, with the rest coming from Europe and Russia. When Canada’s Chalk River reactor, which is dedicated to isotope production, was shut down for a safety upgrade in November 2007, it meant that patients in Canada and elsewhere would have to go without their needed tests and treatment for several weeks. The situation was so dire, that the Canadian Parliament met in an unprecedented special session to mandate the reopening of the reactor and the postponement of the upgrade. The Parliament judged, correctly, that the immediate risk to human lives was far greater than the hypothetical risk for which the reactor was being upgraded. On Dec. 16, 2007, the 50-year-old Chalk River reactor, which supplies half of the world’s radioisotopes, went back on line.

The Chalk River event points out the frustrating situation of nuclear medicine in the United States. Both the Congress and the Executive for years have ignored the many government reports advising more Federal funding for nuclear medicine research and facilities for isotope production. Perhaps as the generation of Baby Boomers ages, and suffers from the diseases of aging, their desire for advanced medical treatment will overrule their knee-jerk opposition to anything nuclear, and these programs will get the support they need.

NAS: More Funding Needed

The most recent of a series of scientific reviews of the nuclear medicine situation is a National Academy of Sciences (NAS) report “Advancing Nuclear Medicine Through Innovation,” issued in September 2007. This report comprehensively describes the promise of nuclear medicine and concludes: “In spite of these exciting possibilities, deteriorating infrastructure and loss of federal research support are jeopardizing the advancement of nuclear medicine. It is critical to revitalize the field to realize its potential.”

But although the NAS report accurately characterizes the present dismal state of U.S. infrastructure in nuclear medicine, its recommendations for isotope production are far too modest. It recommends merely that “a dedicated accelerator and an upgrade to a nuclear reactor should be considered.”

The glaring omission in the NAS review is that it never mentions the Fast Flux Test Reactor (FFTR) at Hanford, Washington. This 400-megawatt sodium-cooled fast reactor was designed to test fusion and fission materials, and to produce isotopes. Yet, for no good reason, and despite a lack...
of domestic facilities to produce large amounts of medical isotopes, the Department of Energy (DOE) decided to shut it down in 1993, and deactivate it in 2001. In 2005, the DOE made a decision to disable the reactor, just months before the same Department announced its new Global Nuclear Energy Partnership (GNEP) program, which calls for a sodium-cooled fast reactor facility.

Fortunately, the FFTF could be reactivated, faster and at a lower expense than building a new facility. According to Dennis Spurgeon, DOE Assistant Secretary for Nuclear Energy, the FFTF “continues to be a potential option” for the GNEP program (see interview with Spurgeon in EIR, Nov. 23, 2007). Restarting the FFTF to produce isotopes would be a step toward meeting the current demand domestically, but an even greater capability is needed.

One of the U.S. suppliers of radioisotopes is the Advanced Test Reactor (ATR) at the Idaho National Laboratory. This is the largest research reactor in the United States, but it was not designed to produce isotopes with short half-lives. As the NAS report notes, there is a plan to upgrade it next year.

Other sources are the High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory; the Brookhaven Linac Isotope Producer (BLIP), at Brookhaven National Laboratory; and the Isotope Production Facility, at Los Alamos National Laboratory, and the Isotope Production Center (LANSCE), at Los Alamos National Laboratory. All of these machines date back to the 1960s and 1970s, and were designed primarily for physics and materials science. According to the NAS report, they cannot “meet the demands of the research community for regular and continuous availability of these radionuclides,” and they are limited by “age-related degradation of the facilities and extended shutdowns for facility maintenance.”

There are a few research reactors at universities, which have helped in the supply of medical isotopes for research, most prominently the Missouri University Research Reactor (MURR). But many university research reactors have been shut down since the anti-nuclear decade of the 1970s, and those remaining have a limited capability for isotope production.

Without an increase in the domestic supply of radioisotopes, the United States will continue to be dependent on other countries and the vagaries of transporting short-lived isotopes over long distances.

**Other Resources Lacking**

The deterioration in the field of nuclear medicine is not limited to domestic production of isotopes. The nation also lacks the reservoir of students in the necessary fields and the infrastructure to ensure that there will be trained personnel in the future. The report states: “There has been a substantial loss of support for the physical sciences and engineering basic to nuclear medicine. There is now no specific programmatic long-term commitment by any federal agency for maintaining high-technology infrastructure (e.g., accelerators, research reactors) or centers for instrumentation and chemistry research and training, which are at the heart of nuclear medicine research and development.”

The NAS report spells out how the isotope program is “not now meeting the needs of the research community.” Public Law 101-101, the report says, “requires full-cost recovery for DOE-supplied isotopes, whether for clinical use or research [and] the lack of new commercially available radiotracers over the past decade may be due in part to this legislation.” In addition, the report notes, the lack of appropriate guidelines of the U.S. Food and Drug Administration for manufacturing radiopharmaceuticals hinders the development and use of new radionuclides.

The NAS report describes the research areas in need of upgrading, stressing the obvious: that there must be long-term financial commitments in order to reap the assured benefits. The report states: “There is an urgent need for the further development of highly specific technology and of targeted radiopharmaceuticals for disease diagnosis.
What Are Radioisotopes?

Radioisotopes or radionuclides are artificially produced, unstable atoms of a chemical element, which have a different number of neutrons in the nucleus, but the same number of protons and the same chemical properties. Many live for only minutes. Their existence is measured in “half-lives,” how long it takes for half of the isotope to disappear.

To produce radioisotopes, a stable isotope is bombarded with fast neutrons that are produced in a nuclear reactor or a particle accelerator. The stable isotope is transmuted into an unstable isotope of the same or a different element.

Smaller proton linear accelerators (linacs), which can be located near a medical facility are also under development, such as that of the Advanced Medical Isotope Corporation in Washington State. The fusion program of the University of Wisconsin at Madison is investigating a new method of producing isotopes in a small fusion reactor. A 1-watt fusion source has already demonstrated that it could provide very short-lived radioisotope doses for use with a PET (positron emission tomography) scanner.

From the time of the Manhattan Project, scientists had realized that nuclear fission would provide an unlimited amount of “tracer and therapeutic radioisotopes.”1 The first major use of a radioisotope was iodine-131, for diagnosis and treatment of thyroid disease. It was found that the thyroid specifically absorbs iodine.

Now, five decades later, isotope technology has developed to a high degree, defining which unique properties of radioisotopes are best at particular tasks. There are now about 200 radioisotopes in use.

Diagnostics and Treatment

Radioisotopes which emit radiation are used today in medical diagnostics, to provide information about how certain organs—the thyroid, bones, heart, liver, and so on—are functioning, without surgery. Radioisotopes can also be used to image the progress of certain treatments, such as shrinking tumors. The radiation does not stay in the body, and there are no side-effects.

The most frequently used radioisotope in medicine today is technetium-99m, which has a half-life of six hours. It is supplied to hospitals in a lead container of its more stable precursor, molybdenum-99, which has a half-life of 66 hours and decays to technetium-99m. The hospital extracts the technetium-99m as needed, and the container is replaced as needed.

Radioisotopes are also used in disease treatment, especially cancer, where radiation-emitting isotopes are attached to some kind of carrier, such as a monoclonal antibody, which targets particular cancer cells. The carrier delivers the radioisotope to the cancer site, where the radiation destroys the cancerous cells, with minimal damage to surrounding tissue.

As noted in the accompanying article, research is ongoing into the use of radioisotopes in treating AIDS and other diseases.